Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > ACADEMIA
ACADEMIA
- JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
- Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
- Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
- JSH2014 GL for Management of Hypertension to Emphasize Transparency, Remove References to Discredited Papers
October 29, 2013
- Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
- Skills for Clinical Studies Required to Become Authorized Hypertension Specialist: JSH
October 28, 2013
- Kyoto Heart Study Chief Investigator to Leave JSH; JSH Ethics Committee Will Continue Investigation
October 28, 2013
- Japan’s First Guidelines for Hematological Malignancy Treatment Compiled by Japanese Society of Hematology
October 24, 2013
- President of Kyoto Prefectural University of Medicine Reprimanded Over Diovan Scandal, Diovan Study Chief Investigator Returns Retirement Allowance
October 17, 2013
- Shiga University of Medical Science to Unveil Diovan Probe Results at Month-End
October 16, 2013
- University of Tokyo Professor Says Results of Diovan Investigations Need to Be Made Open Globally
October 1, 2013
- National University Hospital Council Urges Immediate Check-Up on Hospital’s Clinical Research Systems
September 25, 2013
- AJMC to Unify COI Management Guidelines, Release Draft in December
September 24, 2013
- Use Double-Blind Method to Regain Confidence in Japanese Clinical Trials: Dr Yui of Kyoto Univ. Hospital
September 10, 2013
- The Lancet Announces Retraction of JIKEI Paper on Diovan Trial, Says There’s “Sufficient Doubt”
September 9, 2013
- Tokushukai Group to Cancel Use of Diovan Products at Its 66 Hospitals
August 28, 2013
- Go-Between Faculty Member for Ex-Employee and Osaka City University Received 4 Million Yen in Grants from Novartis
August 26, 2013
- Osaka City University Slams Lead Investigators of Diovan Trials; They “Knew of His Novartis Affiliation”
August 26, 2013
- JSMO Announces Guidance on Prevention and Treatment of Tumor Lysis Syndrome; Rasburicase Recommended for High-risk Patients
August 22, 2013
- Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…